Sunvozertinib (Zegfrovy, 舒沃替尼, 舒沃哲) for EGFR Exon 20 Insertion Non-Small Cell Lung Cancer, for International Families Considering a Review in China
For international patients, caregivers, and physicians, this page explains sunvozertinib (Zegfrovy, 舒沃替尼, 舒沃哲) for EGFR exon 20 insertion non-small cell lung cancer: China’s 23 August 2023 approval, the US accelerated approval on 2 July 2025, the 22 October 2026 US supply announcement, and what a remote review in China can and cannot decide.
Sunvozertinib for EGFR Exon 20 Insertion NSCLC
Sunvozertinib (舒沃替尼, 舒沃哲, Zegfrovy) is approved in China and the United States for non-small cell lung cancer with an EGFR exon 20 insertion. China approved it on 23 August 2023. The FDA granted accelerated approval on 2 July 2025. AstraZeneca announced US specialty-pharmacy supply on 22 October 2026. International families still need the report to name that mutation. The home oncologist says which matched drug or trial can start locally.
On 20 October 2026, KFF Health News reported the case of Debbie Doppelt, a 60-year-old jeweler. In January 2025, New York City’s health systems had no good options for her. KFF described the cancer as an unusual form that mostly afflicts nonsmokers. She had received chemotherapy, immunotherapy, and surgery. December 2024 scans showed spread to the brain, with 10 tiny tumors. She did not qualify for the relevant clinical trials. At Memorial Sloan Kettering, where she was a patient, slight scarring on her lungs made her ineligible for a zipalertinib study. KFF described sunvozertinib as a drug developed in China that targets the mutation driving her tumors. China had approved it in 2023. In January 2025 the FDA had not.
KFF also reported that the FDA had approved amivantamab earlier in 2024, and described it as a drug that targeted the same mutation. The FDA notice is dated 1 March 2024. Her son Max had organized her care since the diagnosis in late 2023. He was concerned about amivantamab’s toxicity. Several doctors he consulted told him that it might not penetrate brain tissue. KFF said US testing of sunvozertinib was limited to late-stage trials in which half the subjects received chemotherapy only, and that this risk was a nonstarter for her.
KFF quoted a doctor telling Max, “Too bad she’s not Chinese. She could go to a pharmacy in China and buy it.” Within hours, mother and son reached friends and relatives. One of them procured a small supply from a contact living in China. A few months later Max flew to Shanghai and returned with 26 boxes. He told KFF he knew of at least 30 Americans who had gone for the drug. KFF wrote that the FDA licensed it in July 2025, and that it was not on the US market as of mid-October 2026. The same article described a 70-year-old woman, whom KFF did not name, who received a six-month supply from China earlier that year. After three months she said it was not working: “My cancer had spread.”
KFF quoted AstraZeneca spokesperson Tara Parsell. She said the company signed an agreement with Dizal on 1 September 2026 to distribute the drug worldwide, and planned US availability by the start of 2027. AstraZeneca’s own release that day said it had completed an exclusive global license and acquired worldwide rights to develop and commercialise Zegfrovy. The drug was already available in China for second-line use, and a US launch was planned for the fourth quarter of 2026. On 22 October 2026, AstraZeneca announced that Zegfrovy was available in the United States through its specialty distribution and pharmacy network, and that health systems’ own specialty pharmacies could also acquire it.
Key points at a glance:
- •Three dates: NMPA approval on 23 August 2023, FDA accelerated approval on 2 July 2025, AstraZeneca’s US supply announcement on 22 October 2026.
- •The US approval requires an FDA-approved test and progression on or after platinum chemotherapy. The China approval also covers progression during platinum chemotherapy, and patients who cannot tolerate it.
- •A 2026 China insurance filing quotes the label dose as 300 mg once daily, with or without food, preferably after food. The FDA notice states 200 mg orally once daily with food.
- •A first-line filing is not an approval. Dizal said both the FDA and China’s CDE had accepted one. AstraZeneca said the FDA had accepted the US filing, and that a filing had been submitted to China’s CDE.
- •The report has to name the exon 20 insertion. In the United States, amivantamab is a separate approved option, including a first-line regimen given with chemotherapy.
- •A remote review uses pathology, NGS, imaging, and prior treatment. The Chinese oncology team judges fit. A coordination service does not recommend a specific drug.
What do the China and US notices say about sunvozertinib?
Sunvozertinib (舒沃替尼; China trade name 舒沃哲; US brand Zegfrovy) is made by Dizal (Jiangsu) Pharmaceutical. The NMPA notice calls it an EGFR tyrosine kinase inhibitor. AstraZeneca describes it as an oral irreversible EGFR inhibitor. The dates below come from the NMPA, Dizal, the FDA, and AstraZeneca. They are not a statement about what one hospital or insurer can dispense today.
What does the China approval say?
On 23 August 2023, China’s National Medical Products Administration approved sunvozertinib tablets for adults with locally advanced or metastatic NSCLC and an EGFR exon 20 insertion, after progression during or after platinum-containing chemotherapy, or if the patient cannot tolerate that chemotherapy. The NMPA notice gives the China trade name as 舒沃哲. It does not name the trial or the dose. Dizal’s 30 August 2026 release calls WU-KONG6 the China registration trial. A 2026 national insurance filing lists the generic name as 舒沃替尼片 and quotes the label: 300 mg, two 150 mg tablets, once daily, with or without food, preferably after food.
The 2023 ASCO abstract of WU-KONG6 says 104 Chinese patients were enrolled and that patients received 300 mg once daily. In the 97-patient efficacy set, the confirmed response rate by blinded independent central review was 60.8% (59 of 97). In the 31 patients with brain metastases at the start of the study, that rate was 48.5% (15 of 31). The Lancet Respiratory Medicine paper says the study was conducted at 37 centres in China, with 104 patients enrolled, and reports a confirmed response rate of 61% (95% CI 50–71) in the 97 patients evaluable for efficacy. That paper lists the most common grade 3 or worse treatment-related events as increased blood creatine phosphokinase (18 of 104), diarrhoea (8 of 104), and anaemia (6 of 104). Those figures describe the studied group. They are not a prediction for one patient.
What does the US accelerated approval say?
On 2 July 2025, the US Food and Drug Administration granted accelerated approval to sunvozertinib (Zegfrovy, Dizal (Jiangsu) Pharmaceutical Co., Ltd.) for adults with locally advanced or metastatic NSCLC whose tumors have an EGFR exon 20 insertion, detected by an FDA-approved test, and whose disease has progressed on or after platinum-based chemotherapy. The same FDA notice approved the Oncomine Dx Express Test as a companion diagnostic. It states the recommended dose as 200 mg orally once daily with food.
The FDA notice evaluates WU-KONG1B. In 85 patients treated at 200 mg orally once daily with food, the confirmed response rate was 46% (95% CI 35, 57) and the duration of response was 11.1 months (95% CI 8.2, not evaluable). The FDA Drug Trials Snapshots page for Zegfrovy, citing the prescribing information, lists 39 responders and states that 72% of them had a response lasting at least six months. AstraZeneca’s 22 October 2026 announcement repeats the 46% response rate, the 11.1-month median among those 39 responders (95% CI 8.2, not estimable), and the 72% figure. That announcement says continued approval may be contingent upon verification and description of clinical benefit in a confirmatory trial. The 2 July 2025 FDA notice does not itself contain that sentence.
Are the China and US doses the same?
The China filing quoted above gives 300 mg once daily, with or without food, preferably after food. The FDA notice gives 200 mg once daily with food. Those are two labeled doses from two documents. The prescribing clinician sets the dose for the patient in front of them.
What did the supply announcements say?
Between 1 September and 22 October 2026, US supply was described in three ways. On 20 October 2026, KFF quoted AstraZeneca spokesperson Tara Parsell: the drug was not on the US market as of mid-October, and the company planned availability by the start of 2027. AstraZeneca’s 1 September 2026 release said a US launch was planned for the fourth quarter of 2026, and that the drug was already available in China for second-line use. On 22 October 2026, AstraZeneca announced US availability through its specialty pharmacy network and through health systems’ own specialty pharmacies. This page does not list stock at a named hospital or insurer. A family needs to ask its own oncology team and pharmacy.
Access in a given hospital, insurer, or country is a separate question from a national announcement. This article does not catalogue those lists.
The approved line of therapy is part of the label. As of AstraZeneca’s 22 October 2026 announcement, the approved uses were still the ones described above, not first-line treatment. On 30 August 2026, Dizal announced that the FDA had accepted a supplemental application for first-line use, based on the phase III WU-KONG28 trial, and that China’s Center for Drug Evaluation had accepted a first-line filing and placed it in priority review. Dizal said WU-KONG28 showed a statistically significant improvement in progression-free survival versus platinum-doublet chemotherapy, with results presented at the 2026 ASCO meeting and published in the New England Journal of Medicine. Dizal also said both the FDA and China’s CDE had granted breakthrough therapy designation for that first-line use. AstraZeneca’s 1 September 2026 release says the same about FDA acceptance, the ASCO presentation, the New England Journal of Medicine, and the two breakthrough designations, and says the first-line filing was submitted to China’s CDE. A designation and an accepted filing are not an approval. This page does not restate the trial’s numerical results.
Accelerated approvals can also be withdrawn. The FDA approved mobocertinib (Exkivity) on 15 September 2021, under accelerated approval, for the same post-platinum EGFR exon 20 insertion setting. The Federal Register of 15 July 2024 records that approval was withdrawn, at Takeda’s request, because the required postmarketing trial did not verify clinical benefit.
The lung cancer page on this site discusses other EGFR inhibitors used in China, including osimertinib, aumolertinib, and furmonertinib. Their labels are separate documents. The sunvozertinib approvals quoted above are written for an EGFR exon 20 insertion. A report has to be read for that wording before anyone treats another EGFR drug as the same choice. See the lung cancer treatment guide.
Does the report name an EGFR exon 20 insertion?
Targeted drugs are approved for a named change in the tumor. A report that says only “EGFR positive,” “EGFR mutant,” or “sensitive EGFR mutation” does not say whether an exon 20 insertion is present. An exon 19 deletion and the L858R point mutation in exon 21 are different written results from an exon 20 insertion. The sunvozertinib approvals quoted above name the insertion.
How targeted cancer drugs find a defined molecular change is the general idea. The practical step is narrower: open the next-generation sequencing (NGS) report, or the single-gene EGFR report, and find the exact variant name. If the paperwork is incomplete, gathering a full diagnosis file comes before any travel question. The guide on understanding the diagnosis before treatment decisions lists documents to gather before a treatment decision.
What the report should make visible
- The gene and the alteration, written as an EGFR exon 20 insertion, with the protein or nucleotide change when the lab provides it
- Whether the result came from tumor tissue, from blood (liquid biopsy), or from both — and the date of the sample
- Other drivers on the same panel, such as ALK, ROS1, MET, RET, KRAS, HER2, and BRAF. An ALK rearrangement, for example, points to a different drug class, including agents discussed in the lorlatinib guide for ALK-positive NSCLC
- The histology and stage. In the ASCO report of WU-KONG6, 31 of 97 patients had brain metastases at study entry, and 15 of those 31 had a confirmed response. That subgroup result is not a statement about untreated or growing brain lesions. The treating team reads the scans.
The next question goes to the home oncology team: which matched drug or trial can start locally now? On 1 March 2024, the FDA approved amivantamab-vmjw (Rybrevant, Janssen Biotech) with carboplatin and pemetrexed for first-line treatment of locally advanced or metastatic NSCLC with an EGFR exon 20 insertion detected by an FDA-approved test. The same notice granted traditional approval for amivantamab-vmjw alone after platinum-based chemotherapy, and said the FDA had previously granted accelerated approval for that use. The notice lists infusion-related reaction among the most common adverse reactions. AstraZeneca said on 1 September 2026 that sunvozertinib was already available in China for second-line use, and on 22 October 2026 that it was available in the US specialty network described above. This page does not list other countries.
Trial rules are written protocol by protocol. In the KFF account, slight scarring on the lungs made Debbie Doppelt ineligible for a zipalertinib trial at Memorial Sloan Kettering. When earlier treatment has already been used, the page on what remains when standard treatment is no longer working can help a family prepare questions. It does not replace the treating oncologist’s recommendation.
What is the difference between treatment in China and bringing the medicine home?
The sections below separate staying with the home oncology team, treatment prescribed by a Chinese oncology team, and the personal carriage described by KFF Health News. This page does not describe how to buy or transport medicine.
What if care stays with the home team?
In the United States, the 1 March 2024 FDA approval of amivantamab-vmjw described above was already a local option when KFF reported the Doppelt case. On 22 October 2026 AstraZeneca said sunvozertinib itself was available through a US specialty pharmacy network. Whether a local drug, a trial, or a wait is reasonable is a question for the home oncologist. Whether a pharmacy stocks sunvozertinib is a different fact from whether the report names an exon 20 insertion.
Records to send to the home team
- Pathology and the full molecular report, naming the exon 20 insertion
- Recent CT or MRI reports, including brain imaging when it has been done
- Dates and responses for chemotherapy, immunotherapy, radiation, and any earlier targeted drug
Who monitors: the local oncologist, or the trial site if the patient enrolls. Supply: the local pharmacy or the trial pharmacy. Whether that team will prescribe sunvozertinib is a question for them.
What does treatment under a Chinese oncology team mean?
This path means a Chinese oncology team reviews the case, decides whether the patient meets criteria for a drug or another plan, prescribes if appropriate, and monitors treatment while the patient is under that team’s care. It is cancer treatment with a responsible clinician. It is a different arrangement from asking someone to purchase boxes for the suitcase.
For families using this service, the first step is a remote multidisciplinary case review before any flight. If the team considers treatment appropriate, cancer treatment coordination in China can help with records, bilingual communication, and the logistics of appointments. Prescribing stays with the oncology team.
Records to send before travel
- The same pathology, NGS, imaging, and treatment history as in the home-team list above
- Translations of the key reports, imaging files, and a short summary from the home oncologist when one is available
- A current medicine list, and any side effects already recorded on earlier treatment
Who monitors: the Chinese oncology team during care in China. The WU-KONG6 side-effect counts are in the first section and again under supportive care below. Dose changes belong to the prescribing team. Supply: medicine prescribed and dispensed as part of that team’s plan. After return: ask the home oncologist whether prescribing can continue, and ask the insurer what it covers. This page has no data on insurance decisions.
What did KFF report about personal carriage?
KFF Health News quoted a US Department of Health and Human Services spokesperson: obtaining medication abroad for personal use is sometimes legal, and the FDA cautions patients about potential safety and quality risks of treatments outside the US regulatory system. This article does not describe how to buy or carry medicine.
Dizal’s 2026 national insurance filing quotes a China label dose of 300 mg, two 150 mg tablets, once daily, with or without food and preferably after food. The FDA notice states 200 mg orally once daily with food. A box from one label is not the dose written on the other label. ChinaMed Waypoint does not arrange the purchase or carriage of medicine.
Questions about CAR-T and other cell therapies belong with CAR-T and cell therapy resources. This page is about sunvozertinib, an oral EGFR inhibitor in the notices cited above, and about the dates of China approval, US accelerated approval, and the US availability announcement.
Want the records read before any travel decision?
A remote review can look at the pathology, the NGS report, recent imaging, and prior treatment, and a Chinese oncology team can say whether a further opinion in China is relevant. The coordination team organises the file. The clinicians decide.
Request a Case ReviewWhat records does a remote review use?
The useful product of a review is a file a specialist can read. ChinaMed Waypoint can help assemble that file and arrange a structured review with a Chinese oncology team. The team judges whether sunvozertinib, amivantamab, a trial, or continued care at home is the appropriate next discussion. The coordination service does not recommend a drug, promise a response, or replace the home oncologist.
Documents a review can use
- Pathology report, including histology
- NGS or EGFR report with the exact variant
- Imaging reports and, when possible, the image files
- Prior regimens, dates, response, and reason for stopping
Questions the review is meant to settle
- Does the variant match a drug that is approved for it?
- Does the applicable label require progression on or after platinum chemotherapy, or does it also cover inability to tolerate platinum?
- Is a local drug or trial a reasonable alternative?
- If travel is considered, who will monitor, and who resumes care at home?
Questions worth taking to the current oncologist
- •Which EGFR alteration is written on the report — exon 19 deletion, L858R, exon 20 insertion, or something else?
- •Which matched drugs or trials can we start here, and what is the expected wait for pharmacy supply?
- •Does the current approval require prior platinum chemotherapy, and have we already received it?
- •If brain metastases are present, are they treated and stable, or do they need their own plan first?
- •If we obtained this medicine under another country’s label, which dose applies, and who will check side effects?
- •If a review in China suggests a plan, will you resume prescribing and scans after we return?
What side effects did WU-KONG6 report?
In the Lancet Respiratory Medicine report of WU-KONG6, the most common grade 3 or worse treatment-related events were increased blood creatine phosphokinase (18 of 104), diarrhoea (8 of 104), and anaemia (6 of 104). The ASCO abstract said the most common treatment-emergent adverse events were similar to those of other EGFR inhibitors, and that the majority were grade 1 or 2. Nutrition, symptom support, Traditional Chinese Medicine, or acupuncture, if used, has to be known to the oncology team prescribing the cancer drug. Tell that team about every other medicine or product being used. See the site’s Traditional Chinese Medicine and supportive care resources. Those pages do not replace the prescribing oncologist.
Frequently Asked Questions
What should families check when a cancer drug is approved in one country before a pharmacy in another can dispense it?
Check three dates separately: when a regulator approved the drug, whether another country has also licensed it, and whether a local pharmacy or hospital can dispense it today. Then confirm the exact mutation on the pathology or NGS report, and ask the home oncology team whether a matched drug or trial is already available. Travel for a structured review in China comes after that. A coordination service can organize records. It does not choose the drug.
What is an EGFR exon 20 insertion, and why does the exact wording on the report matter?
An EGFR exon 20 insertion is a specific change in the EGFR gene. In a 2026 China national insurance submission, Dizal described it as about 2.1% to 2.3% of non-small cell lung cancer in China. The China and US approvals of sunvozertinib name this alteration, so a report that says only “EGFR positive” or “EGFR mutant” does not show that it is present. The treating oncologist interprets the laboratory wording.
Is sunvozertinib the same medicine as osimertinib or other classical EGFR inhibitors?
No. Sunvozertinib (舒沃替尼, 舒沃哲, Zegfrovy) is a different medicine from osimertinib. The NMPA notice calls it an EGFR tyrosine kinase inhibitor, and AstraZeneca describes it as an oral irreversible EGFR inhibitor. The US approval requires an FDA-approved test and progression on or after platinum chemotherapy; the China approval also covers progression during platinum chemotherapy, and patients who cannot tolerate it. On 1 March 2024 the FDA approved amivantamab-vmjw for this same mutation, with carboplatin and pemetrexed in the first-line regimen and alone after progression on or after platinum-based chemotherapy. The treating oncologist decides whether any of these drugs fits.
What is the difference between treatment in China and bringing cancer medicine home from China?
Treatment in China means a Chinese oncology team reviews the records, prescribes if appropriate, and monitors side effects. Personal carriage is the route KFF Health News described: a friend or relative procured a small supply from a contact in China, and the patient’s son later returned from Shanghai with 26 boxes. KFF quoted a US health department spokesperson saying that obtaining medication abroad for personal use is sometimes legal, and that the FDA cautions patients about potential safety and quality risks outside the US system. The China filing quotes 300 mg once daily, with or without food, preferably after food. The FDA notice states 200 mg once daily with food. ChinaMed Waypoint does not arrange purchase or carriage.
Can a coordination service recommend sunvozertinib or tell a family to travel for it?
No. ChinaMed Waypoint is a coordination service, not a medical provider. It can help organize pathology, NGS, imaging, and prior treatment records for a remote multidisciplinary review. The Chinese oncology team decides whether a drug, a trial, or another plan is appropriate. A trial’s group response rate does not predict one patient’s result, and approval does not mean every patient with a similar diagnosis should receive the drug.
Sources for the dates, doses, and the reported case
- KFF Health News, 20 October 2026 — Debbie and Max Doppelt, the doctor’s remark, the Shanghai refill, the count of Americans Max reported, the unnamed patient whose cancer spread, and the FDA caution on medicine obtained abroad.
- China NMPA, 23 August 2023 — approval of sunvozertinib tablets (舒沃哲), including platinum intolerance.
- ASCO 2023 abstract for WU-KONG6 — 104 Chinese patients enrolled, 300 mg once daily, confirmed response 60.8% (59/97), and the brain-metastasis subgroup. The Lancet paper places the study at 37 centres in China. Published later in The Lancet Respiratory Medicine, which reports a confirmed response of 61% (95% CI 50–71) and the grade 3 or worse event counts.
- FDA, 2 July 2025 — accelerated approval, Oncomine Dx Express Test, 200 mg dose, and the WU-KONG1B response rate and duration in the notice. The FDA Drug Trials Snapshots page lists the 39 responders and the 72% figure, citing the prescribing information.
- AstraZeneca, 1 September 2026 — completed global license; drug already available in China for second-line use.
- AstraZeneca, 22 October 2026 — US availability, the 200 mg dose, the WU-KONG1B figures repeated there, and the statement that continued approval may be contingent upon verification and description of clinical benefit in a confirmatory trial.
- Dizal, 30 August 2026 — FDA acceptance of the first-line filing, CDE priority review, breakthrough therapy designations, and WU-KONG6 described as the China registration trial. The generic name 舒沃替尼, the 2.1% to 2.3% figure for China, and the quoted 300 mg label dose are in Dizal’s 2026 national insurance submission.
- FDA, 1 March 2024 — amivantamab for EGFR exon 20 insertion NSCLC.
- US Federal Register, 15 July 2024 — withdrawal of mobocertinib.
Medical disclaimer: ChinaMed Waypoint is a coordination service, not a medical provider. Nothing in this article constitutes medical advice. Approval dates, doses, and commercial supply change, and families should confirm current access with their own oncology team and pharmacy. All treatment decisions should be made in consultation with a qualified oncologist or thoracic oncology specialist who knows the patient’s full history, molecular profile, and prior treatment.
Related Guides
Lung Cancer Treatment in China: Targeted Therapy & Immunotherapy
Classical EGFR inhibitors, ALK and MET targeted drugs, immunotherapy, and how international patients request a structured review.
How Lorlatinib Works for ALK-Positive NSCLC
ALK rearrangement is a different molecular target from an EGFR exon 20 insertion, and it points to a different sequence of drugs.
What Remains When Standard Treatment Is No Longer Working
How families and physicians reassess biomarker results, later-line drugs, trials, and a second opinion after earlier treatment stops helping.
Request a Structured Case Review
If a cancer drug is approved in China and you cannot tell whether it matches the report, or whether it can be started at home, a structured review can clarify the next question before any travel.